Wolfgang Reith

Dr. Wolfgang Reith


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
MKMonika Killer-Oberpfalzer
Monika Killer-Oberpfalzer
NKN. Kocer
N. Kocer
CGC.J. Griessenauer
C.J. Griessenauer
HJH. Janssen
H. Janssen
TET. Engelhorn
T. Engelhorn
MMMarkus A. Möhlenbruch
Markus A. Möhlenbruch
BACKGROUND AND PURPOSE: Endoluminal reconstruction with flow-diverting stents represents a widely accepted technique for the treatment of complex intracranial aneurysms. This European registry study analyzed the initial experience of 15 neurovascular centers with the Flow-Redirection Intraluminal Device (FRED) system. MATERIALS AND METHODS: Consecutive patients with intracranial aneurysms treated with the FRED between February 2012 and March 2015 were retrospectively reviewed. Complications and adverse events, transient and permanent morbidity, mortality, and occlusion rates were evaluated. RESULTS: During the defined study period, 579 aneurysms in 531 patients (median age, 54 years; range, 13–86 years) were treated with the FRED. Seven percent of patients were treated in the acute phase (≤3 days) of aneurysm rupture. The median aneurysm size was 7.6 mm (range, 1–36.6 mm), and the median neck size 4.5 mm (range, 1–30 mm). Angiographic follow-up of >3 months was available for 516 (89.1%) aneurysms. There was progressive occlusion witnessed with time, with complete occlusion in 18 (20%) aneurysms followed for up to 90 ± 14 days, 141 (82.5%) for 180 ± 20 days, 116 (91.3%) for 1 year ± 24 days, and 122 (95.3%) aneurysms followed for >1 year. Transient and permanent morbidity occurred in 3.2% and 0.8% of procedures, respectively. The overall mortality rate was 1.5%. CONCLUSIONS: This retrospective study in real-world patients demonstrated the safety and efficacy of the FRED for the treatment of intracranial aneurysms. In most cases, treatment with a single FRED resulted in complete angiographic occlusion at 1 year.

6 March 2018 in Der Radiologe
Verified
Journal Article
Closed access
PDF file
WRWolfgang Reith
Wolfgang Reith

23 July 2012 in Brain Research
Verified
Journal Article
Closed access
HZHubert D. Zimmer
Hubert D. Zimmer
CPChristian Popp
Christian Popp
WRWolfgang Reith
Wolfgang Reith
CKChristoph Krick
Christoph Krick

24 May 2018 in Der Radiologe
Verified
Journal Article
Closed access
PDF file
WRWolfgang Reith
Wolfgang Reith
AHA. Haussmann
A. Haussmann

27 February 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
CGC.J. Griessenauer
C.J. Griessenauer
MMMarkus A. Möhlenbruch
Markus A. Möhlenbruch
PHP. Hendrix
P. Hendrix
CUC. Ulfert
C. Ulfert
CICivan Islak
Civan Islak
MKMonika Killer-Oberpfalzer
Monika Killer-Oberpfalzer
BACKGROUND AND PURPOSE: Flow diversion for the posterior circulation remains a promising treatment option for selected posterior circulation aneurysms. The Flow-Redirection Intraluminal Device (FRED) system has not been previously assessed in a large cohort of patients with posterior circulation aneurysms. The purpose of the present study was to assess safety and efficacy of FRED in this location. MATERIALS AND METHODS: Consecutive patients with posterior circulation aneurysms treated at 8 centers participating in the European FRED study (EuFRED) between April 2012 and January 2019 were retrospectively reviewed. Complication and radiographic and functional outcomes were evaluated. RESULTS: Eighty-four patients (median age, 54 years) with 84 posterior circulation aneurysms were treated with the FRED. A total of 25 aneurysms (29.8%) had previously ruptured, even though most aneurysms were diagnosed incidentally (45.2%). The intradural vertebral artery was the most common location (50%), and saccular, the most common morphology (40.5%). The median size was 7 mm. There were 8 (9.5%) symptomatic thromboembolic and no hemorrhagic complications. Thromboembolic complications occurred mostly (90.9%) in nonsaccular aneurysms. On last follow-up at a median of 24 months, 78.2% of aneurysms were completely occluded. Functional outcome at a median of 27 months was favorable in 94% of patients. All mortalities occurred in patients with acute subarachnoid hemorrhage and its sequelae. CONCLUSIONS: The largest cohort of posterior circulation aneurysms treated with the FRED to date demonstrated favorable safety and efficacy profiles of the device for this indication. Treatment in the setting of acute subarachnoid hemorrhage was strongly related to mortality, regardless of whether procedural complications occurred.

1 January 2007 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
HSHarald Scherk
Harald Scherk
MBMartin Backens
Martin Backens
TSThomas Schneider-Axmann
Thomas Schneider-Axmann
JUJuliana Usher
Juliana Usher
CKClaudia Kemmer
Claudia Kemmer
OGOliver Gruber
Oliver Gruber